Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Three projects from MSD were amongst 10 from across the University to receive funding from the second-round of the Public Engagement with Research Seed Fund [http://www.ox.ac.uk/research/public-engagement/support-researchers].

Dr Marta Valente Pinto, is based in the Oxford Vaccine Group, part of the Department of Paediatrics, where she studies Whooping cough, a highly contagious respiratory disease that, although to some extent preventable by vaccines, continues to cause a significant number of infections in developed countries. Her project will involve the creation and delivery of workshops in Thames Valley Primary and Secondary Schools to help children and parents understand more about the disease, and to make more informed decisions about vaccinations.

Dr Marco J. Haenssgen, based in the Centre for Tropical Medicine & Global Health, part of the Nuffield Department of Medicine, received funding  to evaluate the process and impact of health-themed science theatre as part of ongoing public engagement activities at the Mahidol Oxford Tropical Medicine Research Unit. In order to engage the public with its research, MORU is collaborating with B-floor Theatre to produce a performance entitled Fishy Clouds, which explores antimicrobial resistance through puppet plays for both children and adults in Thailand. The social outcomes of drama performances are difficult to evaluate and little guidance exists in the evaluation research literature. This project will test out methods for evaluation, and in doing so inform the theory and practice of evaluating such engagement activities for others. 

Simon Knight, based at the Oxford Transplant Centre, part of the Nuffield Department of Surgical Sciences, was awarded funding to develop an online patient advisory panel for renal and transplant research in Oxford, which will provide a patient perspective on upcoming research projects and patient materials.

Similar stories

First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy

COVID-19 Vaccinology

University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.

University spinout PepGen awarded major financing to target Duchenne muscular dystrophy

Awards & Appointments Neuromuscular Diseases

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.

Oxford University breakthrough on global COVID-19 vaccine

COVID-19 Vaccinology

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.

Oxford coronavirus vaccine produces strong immune response in older adults

COVID-19 Vaccinology

The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.

SIMON Says…

Vaccinology

Researchers at Oxford Vaccine Group have developed machine learning software to predict the efficacy of flu vaccines, offering huge potential for other vaccine research.

Coronavirus: the road to vaccine roll-out is always bumpy, as 20th-century pandemics show

COVID-19 Vaccinology

Public trust is key to a successful immunisation programme, writes Samantha Vanderslott in a piece for The Conversation.